Search Within

Paul Marks

  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (7)
  2. Meeting Abstract (5)
Groups
  1. Department of Medicine (12)
  2. Genitourinary Oncology Service (12)
  3. Solid Tumor Oncology Division (12)
  4. Nursing (5)
  5. Center for Hematologic Malignancies (4)
  6. Adult Leukemia (2)

More Groups

People
  1. Howard Scher (12)
  2. Richard Rifkind (10)
  3. Victoria Richon (6)
  4. Lisa Butler-van Den Heuvel (5)
  5. Owen O'connor (5)
  6. William Kelly (5)

More People

Years
  1. 2007 (1)
  2. 2005 (1)
  3. 2003 (2)
  4. 2002 (4)
  5. 2001 (1)
  6. 2000 (2)

More Years

Publications
  1. Clinical Cancer Research (3)
  2. Proceedings of the American Association for Cancer Research Annual Meeting (2)
  3. Blood (1)
  4. Cancer Research (1)
  5. European Journal of Cancer (1)
  6. Journal of Clinical Epidemiology (1)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. Elsevier Inc. (2)
  3. American Society of Clinical Oncology (1)
  4. American Society of Hematology (1)
  5. National Academy of Sciences (1)

Results (12)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
    Journal Article

    Marrocco, D. L.; Tilley, W. D.; Bianco-Miotto, T.; Evdokiou, A.; Scher, H. I.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.; Butler, L. M.
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    Journal Article

    Kelly, W. K.; O'Connor, O. A.; Krug, L. M.; Chiao, J. H.; Heaney, M.; Curley, T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J. P.; Schwartz, L.; more...
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Phase I clinical trial of an oral histone deacetylase inhibitor: Suberoylanilide hydroxamic acid (SAHA)
    Meeting Abstract

    Kelly, W. K.; O'connor, O.; Richon, V. M.; Curley, T.; Richardson, S.; Thapi, D.; Chiao, J. H.; Rifkind, R. A.; Marks, P. A.; Scher, H. I.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously
    Journal Article

    Kelly, Wm K.; Richon, V. M.; O'connor, O.; Curley, T.; Macgregor-Cortelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; more...
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces thioredoxin-binding protein-2 which blocks thioredoxin function
    Meeting Abstract

    Butler, L. M.; Zhou, X.; Scher, H. I.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save
  • A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
    Meeting Abstract

    Kelly, W.; O'connor, O.; Richon, V. M.; Tong, W.; Rao, T. D.; Chiao, J.; O'Brien, J. P.; Rifkind, R. A.; Marks, P. A.; Scher, H. I.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)
    Meeting Abstract

    O'Connor, O. A.; Richon, V.; Moskowitz, C. H.; Zelenetz, A. D.; Macgregor-Cortelli, B.; Curly, T.; Richardson, S.; Tong, W.; Rifkind, R.; Marks, P.; more...
    Blood (2002)

    Fulltext@MSK | Save
  • The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
    Journal Article

    Butler, L. M.; Zhou, X.; Xu, W. S.; Scher, H. I.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.
    Proceedings of the National Academy of Sciences of the United States of America (2002)

    Fulltext@MSK | Save
  • Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase
    Journal Article

    Butler, L. M.; Webb, Y.; Agus, D. B.; Higgins, B.; Tolentino, T. R.; Kutko, M. C.; LaQuaglia, M. P.; Drobnjak, M.; Cordon-Cardo, C.; Scher, H. I.; more...
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • Hybrid polar inhibitors of histone deacetylase suppress the growth of the CWR22 human prostate cancer xenograft
    Meeting Abstract

    Butler, L. M.; Higgins, B.; Fox, W. D.; Agus, D. B.; Cordon-Cardo, C.; Scher, H. I.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.
    Proceedings of the American Association for Cancer Research Annual Meeting (2000)

    Fulltext@MSK | Save